The achievements and challenges of the African Programme for Onchocerciasis Control (APOC).

The main strategy of APOC, of community-directed treatment with ivermectin (CDTI), has enabled the programme to reach, empower and bring relief to remote and under-served, onchocerciasis-endemic communities. With CDTI, geographical and therapeutic coverages have increased substantially, in most areas, to the levels required to eliminate onchocerciasis as a public-health problem. Over 20 million people received treatment in 2000. APOC has also made effective use of the combination of the rapid epidemiological mapping of onchocerciasis (REMO) and geographical information systems (GIS), to provide information on the geographical distribution and prevalence of the disease. This has led to improvements in the identification of CDTI-priority areas, and in the estimates of the numbers of people to be treated. A unique public-private-sector partnership has been at the heart of APOC's relative success. Through efficient capacity-building, the programme's operations have positively influenced and strengthened the health services of participating countries. These laudable achievements notwithstanding, APOC faces many challenges during the second phase of its operations, when the full impact of the programme is expected to be felt. Notable among these challenges are the sustainability of CDTI, the strategy's effective integration into the healthcare system, and the full exploitation of its potential as an entry point for other health programmes. The channels created for CDTI, could, for example, help efforts to eliminate lymphatic filariasis (which will feature on the agenda of many participating countries during APOC's Phase 2). However, these other programmes need to be executed without compromising the onchocerciasis-control programme itself. Success in meeting these challenges will depend on the continued, wholehearted commitment of all the partners involved, particularly that of the governments of the participating countries.

Monitoring community-directed treatment programmes for sustainability: lessons from the African Programme for Onchocerciasis Control (APOC).

Community-directed treatment is a relatively new strategy that was adopted in 1997 by the African Programme for Onchocerciasis Control (APOC), for large-scale distribution of ivermectin (Mectizan). Participatory monitoring of 39 of the control projects based on community-directed treatment with ivermectin (CDTI) was undertaken from 1998-2000, with a focus on process implementation of the strategy and the predictors of sustainability. Data from 14,925 household interviews in 2314 villages, 183 complete treatment records, 382 focus-group discussions, and the results of interviews with 669 community leaders, 757 trained community-directed drug distributors (CDD) and 146 health personnel (in 26 projects in four countries) were analysed. The data show that CDD dispensed ivermectin to 65.4% of the total population (71.2% of the eligible population), with no significant gender differences in coverage (P > 0.05). Treatment coverage ranged from 60.2% of the eligible subjects in Cameroon to 76.9% in Uganda. There was no significant relationship between the provision of incentives to CDD and treatment coverage (P > 0.05). The frequency of treatment refusal was highest in Cameroon (29.2%). Although most (72.1%) of the communities investigated selected their CDD on the basis of a community decision at a village meeting, only 37.9% chose their distribution period in the same way. There is clearly a need to improve communication strategies, to address the issues of absentees and refusals, to emphasise community ownership and to de-emphasise incentives for CDD. The investigation of the 'predictor indicators' of sustainability should enable APOC to understand the determinants of project performance and to initiate any appropriate changes in the programme.

APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. African Programme for Onchocerciasis Control.

Since its inauguration in 1995, the African Programme for Onchocerciasis Control (APOC) has made significant progress towards achieving its main objective: to establish sustainable community-directed treatment with ivermectin (CDTI) in onchocerciasis-endemic areas outside of the remit of the Onchocerciasis Control Programme in West Africa (OCP). In the year 2000, the programme, in partnership with governments, non-governmental organizations and the endemic communities themselves, succeeded in treating 20,298,138 individuals in 49,654 communities in 63 projects in 14 countries. Besides the distribution of ivermectin, the programme has strengthened primary healthcare (PHC) through capacity-building, mobilization of resources and empowerment of communities. The community-directed-treatment approach is a model that can be adopted in developing other community-based health programmes. The approach has also made it possible to bring to the poor some measure of intervention in some other healthcare programmes, such as those for malaria control, eye care, maternal and child health, nutrition and immunization. CDTI presents, at all stages of its implementation, a unique window of opportunity for promoting the functional integration of healthcare activities. For this to be done successfully and in a co-ordinated manner, adequate funding of CDTI within PHC is as important as an effective sensitization of the relevant policy-makers, healthworkers and communities on the value of integration (accompanied by appropriate training at all levels). Evaluation of the experiences in integration of health services, particularly at community level, is crucial to the success of the integration.

Eliminating onchocerciasis after 14 years of vector control: a proved strategy.

From 1976 through 1989, weekly aerial spraying operations against blackflies were carried out along the rivers of a wide savanna area of West Africa (approximately 700,000 km(2)) where onchocerciasis was hyperendemic. The level of endemicity began to decrease significantly after 4 years of vector control and became very low in 1989. This situation has been maintained without any vector control activity or chemotherapy, and no incidence of any new cases has been detected. An ophthalmological study carried out in 2000 has confirmed these good results, showing only cicatricial ocular lesions in the examined population. These results led to the conclusion that 14 years of vector control may achieve long-term elimination of onchocerciasis, even in the absence of chemotherapy, provided that the treated areas are not subjected to any contamination by exogenous parasites carried in infected humans or flies.

Delivery systems and cost recovery in Mectizan treatment for onchocerciasis.

The efficiency of on-going delivery systems and cost recovery in Mectizan (ivermectin, MSD) treatment for onchocerciasis are reviewed. The search is on for an effective system of Mectizan delivery, involving drug procurement, delivery from port to districts and distribution to eligible persons, which can be sustained by the endemic countries for many years. The mechanisms for procuring and clearing the drug at the ports, and the drug's integration into the existing delivery systems of each national health service, need to be improved. Although large-scale treatments by mobile teams or community-based methods evidently achieve high and satisfactory rates of coverage, they also incur high recurrent costs which have to be covered by external partners and are not sustainable by national health services. Cost-sharing is considered an important factor in a sustainable delivery system and community-directed treatment, in which the community shares the cost and ownership of local distribution and is empowered to design and implement it, is likely to be more cost-effective and sustainable.

Diagnostics in onchocerciasis: future challenges.

The classical method of determining the prevalence and intensity of onchocercal infection is by the demonstration and counting of microfilariae in biopsies obtained by skin snipping. Although very specific, this technique is inadequate for detecting early, light or prepatent infections, and is also becoming increasingly unacceptable to the populations investigated. The prolonged clearing effect that Mectizan (ivermectin, MSD) treatment has on skin microfilariae also renders the skin-snip method of diagnosis less appropriate in areas with Mectizan treatment. Given all these factors, the greater challenge in the area of diagnostics for onchocerciasis is to develop a less invasive, adequately sensitive, and equally specific diagnostic test, either to replace or to be an adjunct to the present skin-snip method. This challenge is being addressed, with at least three new diagnostic tests for onchocerciasis under development: an immunological assay, based on a three-antigen cocktail; a PCR-based assay, which may also be used for 'pool screening' of blackflies; and the diethylcarbamazine (DEC) patch test. Of all these tests, the DEC patch test seems to fit best the criteria of an ideal test. The PCR assay would be better than the patch test if the cost of using it could be reduced substantially.

The impact of Mectizan on the transmission of onchocerciasis.

For many years there was no suitable drug available for the control of onchocerciasis. The advent of Mectizan (ivermectin, MSD; an effective microfilaricide), its registration in October 1987 for the treatment of human onchocerciasis, and its suitability for large-scale application were major break-throughs in the control of human onchocerciasis via chemotherapy. Several studies, both fly-feeding experiments and community trials, have established that Mectizan treatment causes a significant reduction in the transmission of infection. Although long-term treatment in some isolated foci (such as occur in the New World and in some hypo- and meso-endemic areas elsewhere) appears to interrupt transmission, more prolonged treatment is required to prove if transmission can be stopped. Advantage could be taken of the significant impact of Mectizan on transmission by giving treatment while or just before transmission by blackflies is most intense.

Control of onchocerciasis: challenges for the future.

The control of onchocerciasis has grown over the last two decades to attain global dimensions. This rapid growth poses challenges that are technical and managerial in nature. Appropriate control measures have to be applied to eliminate the disease as a worldwide, public-health problem and prevent the problem recurring. Novel tools and innovative approaches, both for control and surveillance activities, will have to be developed. The health systems of the affected countries need not only to be directly involved in control activities but also to direct operations and have adequate resources to run them successfully.

Blackfly control: what choices after onchocerciasis?

Blackflies are reappearing in areas of West Africa where they used to be controlled with insecticides because they were vectors of the parasite Onchocerca volvulus. Even though they no longer transmit onchocerciasis in these areas they can hinder optimal land use through their biting behaviour. The authors discuss the problems associated with resuming the use of insecticides to control the blackfly and recommend that ground treatment be restricted to areas where it is likely to be effective on a continuing basis. In communities lacking technical and financial resources the only alternative consists of individual protection through the use of repellents or protective clothing.

PIP: Biting insects can be a major inconvenience to people and can even cripple socioeconomic development. Since the transmission of Onchocerca can be blocked by destroying the blackfly vector in its larval stage, blackfly control has been practiced in West Africa since 1975 at the regional level as part of the Onchocerciasis Control Program. Since development of the insect from egg to nymph rarely takes longer than 1 week, spraying is conducted at weekly intervals. Treatments are delivered mainly from the air due to the large number of breeding sites and the difficulty of reaching most of them overland. Vector control remains the preferred approach to onchocerciasis control in regions open to reinfection by blackflies from untreated areas in which the disease is hyperendemic. Aerial spraying, however, has ceased in regions where there is virtually no longer any risk of contracting onchocerciasis. Blackflies are therefore reappearing in areas of West Africa where they used to be controlled with insecticides. Even though these flies no longer transmit onchocerciasis in the areas, their biting behavior can thwart the optimal use of land. With certain exceptions, controlling blackflies is not necessarily the best way of ensuring the long-term development of areas freed from onchocerciasis. Since commercially available products, usually based upon pyrethroids, are too expensive for most communities concerned, and protective clothing is unfeasible due to their high cost and the tropical climate, an inventory of locally-used repellents is being prepared for use.

Onchocerciasis control: the APOC strategy.

PIP: Onchocerciasis represents a serious public health problem in tropical Africa and parts of Central and South America and Yemen. The adult female parasite lives an average of 10-11 years in the human host, producing millions of microfilariae that invade the tissues of the skin and eye. There is a strong association between the parasite load and the severity of the clinical manifestations of the disease. Of the approximately 17.5 million Africans affected by the disease, 15 million live in the 19 countries participating in the African Program for Onchocerciasis Control (APOC). In the APOC countries, up to 600,000 people are blind or have severe visual impairment and 80% of the total population suffers from onchocercal skin disease and itching. The remaining victims live in the 11 countries of the Onchocerciasis Control Program in West Africa (OCP), where the parasite is on the brink of being eliminated--a factor that has benefited socioeconomic development. The OCP combined vector control with use of the microfilaricide ivermectin. APOC has set the goal of establishing within the next 12 years effective, sustainable, community-based ivermectin treatment programs as well as environmentally safe vector control. An overall coverage rate of 70% of the target population is required for eventual elimination of the disease. Since ivermectin does not interrupt transmission of infection, the regimen must be continued for at least 20 years to ensure long-term control. The rapid epidemiological mapping method has been used to delineate the endemicity levels in most APOC countries.^ieng

Twenty-two years of blackfly control in the onchocerciasis control programme in West Africa.

Twenty-two years after the launch of the Onchocerciasis Control Programme in West Africa (OCP), Jean-Marc Hougard and colleagues critically review the vector-control strategy adopted. They go on to identify the few hydrological basins where transmission of the infection remains difficult to control, to analyse the causes and to propose appropriate corrective measures on a case-by-case basis. Most of these measures, which are mainly based on ivermectin chemotherapy, will continue to be applied after the end of the OCP in 2002, under the control of the countries concerned.

Global data on blindness.

Globally, it is estimated that there are 38 million persons who are blind. Moreover, a further 110 million people have low vision and are at great risk of becoming blind. The main causes of blindness and low vision are cataract, trachoma, glaucoma, onchocerciasis, and xerophthalmia; however, insufficient data on blindness from causes such as diabetic retinopathy and age-related macular degeneration preclude specific estimations of their global prevalence. The age-specific prevalences of the major causes of blindness that are related to age indicate that the trend will be for an increase in such blindness over the decades to come, unless energetic efforts are made to tackle these problems. More data collected through standardized methodologies, using internationally accepted (ICD-10) definitions, are needed. Data on the incidence of blindness due to common causes would be useful for calculating future trends more precisely.